Relationship between antigenicity and immunogenicity of chimeric hepatitis B virus core particles carrying HIV type 1 epitopes

AIDS Research and Human Retroviruses

Volumn 13, Issue 1, 1997, Pages 41-51

  Grene, Edith ^a,b   Mezule, Guna ^b   Borisova, Galina ^b   Pumpens, Paul ^b   Bentwich, Zvi ^c   Arnon, Ruth ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b UNIVERSITY OF LATVIA   (Latvia)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANTIGENICITY; ARTICLE; CLINICAL ARTICLE; FEMALE; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS CORE;

EID: 0031011936     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1997.13.41     Document Type: Article

References (52)

1. Norley S and Kurth R: Vaccination against HIV. Immunobiology 1992;184:193-207.
2. Emini EA and Putney SD: Human immunodeficiency virus. Biotechnology 1992;20:309-326.
3. Karzon DT, Bolognesi DP, and Koff WC: Development of a vaccine for the prevention of AIDS: A critical appraisal. Vaccine 1992;10:1039-1052.
4. Bolognesi DP: The immune response to HIV: Implications for vaccine development. Semin Immunol 1993;5:203-214.
5. Hoth DF, Bolognesi DP, Corey L, and Vermund SH: NIH conference. HIV vaccine development: A progress report. Ann Intern Med 1994;121:603-611.
6. Dewar RL, Natarajan V, Vasudevachari MB, and Salzman NP: Synthesis and processing of human immunodeficiency virus type 1 envelope proteins encoded by a recombinant human adenovirus. J Virol 1989;63:129-136.
7. Warner JF, Anderson CG, Laube L, Jolly DJ, Townsend K, Chada S, and St. Louis D: Induction of HIV-specific CTL and antibody responses in mice using retroviral vector-transduced cells. AIDS Res Hum Retroviruses 1991;7:645-655.
8. Belshe RB, Clements ML, Dolin R, Graham BS, McElrath J, Gorse GJ, Schwartz D, Keefer MC, Wright P, Corey L, Bolognesi DP, Matthews TJ, Stablein DM, O'Brien FS, Eibl M, Dorner F, and Koff W: Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. J Infect Dis 1993;168:1387-1395.
9. Paul NL, Marsh M, McKeating JA, Schulz TF, Liljestrom P, Garoff H, and Weiss RA: Expression of HIV-1 envelope glycoproteins by Semliki Forest virus vectors. AIDS Res Hum Retroviruses 1993;9:963-970.
10. Hu SI, Kosowski SG, and Schaaf KF: Expression of envelope glycoproteins of human immunodeficiency virus by an insect virus vector. J Virol 1987;61:3617-3620.
11. Barr PJ, Steimer KS, Sabin EA, Parkes D, George-Nascimento C, Stephans JC, Powers MA, Gyenes A, Van Nest GA, Miller ET, et al.: Antigenicity and immunogenicity of domains of the human immunodeficiency virus (HIV) envelope polypeptide expressed in the yeast Saccharomyces cerevisiae. Vaccine 1987;5:90-101.
12. Hone DM, Lewis GK, Beier M, Harris A, McDaniels T, and Fouts TR: Expression of human immunodeficiency virus antigens in an attenuated Salmonella typhi vector vaccine. Dev Biol Stand 1994;82:159-162.
13. Fuerst TR, Stover CK, and de la Cruz VF: Development of BCG as a live recombinant vector system: Potential use as an HIV vaccine. Biotechnol Ther 1991;2:159-178.
14. Zagury D, Bernard J, Cheynier R, Desportes I, Leonard R, Fouchard M, Reveil B, Ittele D, Lurhuma Z, Mbayo K, Wane J, Salaun J-J, Goussard B, Dechazal L, Burny A, Nara P, and Gallo RC: A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS. Nature (London) 1988;332:728-731.
15. Schwartz DH, Gorse G, Clements ML, Belshe R, Izu A, Duliege AM, Berman P, Twaddell T, Stablein D, Sposto R, Siliciano R, and Matthews T: Induction of HIV-1 neutralizing and syncytium-inhibiting antibodies in uninfected recipients of HIV-1 IIIB rgp120 subunit vaccine. Lancet 1993;342:69-73.
16. Berzofsky JA: Development of artificial vaccines against HIV using defined epitopes. FASEB J 1991;5:2412-2418.
17. Michel ML, Mancini M, Riviere Y, Dormont D, and Tiollais P: T-and B-lymphocyte responses to human immunodeficiency virus (HIV) type 1 in macaques immunized with hybrid HIV/hepatitis B surface antigen particles. J Virol 1990;64:2452-2455.
18. Michel ML, Mancini M, Schlienger K, and Tiollais P: Recombinant hepatitis B surface antigen as a carrier of human immunodeficiency virus epitopes. Res Virol 1993;144:263-267.
19. Razanskas R, Borisova G, Pumpens R, and Sasnauskas K: Expression and analysis of chimeric viral proteins in the yeast Saccharomyces cerevisiae. Yeast 1995;11:15-26.
20. Stahl SJ and Murray K: Immunogenicity of peptide to hepatitis B virus core antigen. Proc Natl Acad Sci USA 1989;86:6283-6287.
21. Borisova GP, Berzins I, Pushko PM, Pumpen P, Gren EJ, Tsibinogin VV, Loseva V, Ose V, Ulrich R, Siakkou H, and Rosenthal HA: Recombinant core particles of hepatitis B virus exposing foreign antigenic determinants on their surface. FEBS Lett 1989;259:121-124.
22. Ulrich R, Borisova GP, Möhring R, Lätzsch I, Ose VP, Berzins IG, Dreilina DE, Pushko PM, Tsibinogin VV, Pumpen PP, Rosenthal HA, and Gren EJ: Exposure of HIV-1 gp41 transmembrane protein epitopes on the surface of hepatitis B core antigen capsids. Bioorg Chem 1990;16:1283-1285. [in Russian]
23. Moriarty AM, McGee JS, Winslow B, Inman D, Leturcq DJ, Thornton GB, Hughes JL, and Milich DR: Expression of HIV Gag and Env B-cell epitopes on the surface of HBV core particles and analysis of the immune responses generated to those epitopes. In: Vaccines 90 (Brown F, Chanock RM, Ginsberg HS, and Lerner RA, Eds.). Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1990, pp. 225-229.
24. Ulrich R, Borisova GP, Gren E, Berzin I, Pumpen P, Eckert R, Ose V, Siakkou H, Gren EJ, von Baehr R, and Kruger DH: Expression and immunogenicity of recombinant core particles of hepatitis B virus containing epitopes of human immunodeficiency virus 1 core antigen. Arch Virol 1992;126:321-328.
25. Von Brunn A, Reichhuber C, Brand M, Bechowsky B, Gurtler L, Eberle J, Kleinschmidt A, Erfle V, and Schodel F: The principal neutralizing determinant (V3) of HIV-1 induces HIV-1-neutralizing antibodies upon expression on HBcAG particles. In: Vaccines 93 (Lerner RA, Ginsberg HS, Chanock RM, and Brown F, Eds.). Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1993, pp. 159-165.
26. Von Brunn A, Brand M, Reichhuber C, Morys-Wortmann C, Deinhardt F, and Schodel F: Principal neutralizing domain of HIV-1 is highly immunogenic when expressed on the surface of hepatitis B core particles. Vaccine 1993;11:817-824.
27. Adams SC, Dawson KM, Gull K, Kingsman SM, and Kingsman AJ: The expression of hybrid HIV:Ty virus-like particles in yeast. Nature (London) 1987;329:68-70.
28. Griffiths JC, Berrie EL, Holdsworth LN, Moore JP, Harris SJ, Senior JM, Kingsman SM, Kingsman AJ, and Adams SE: Induction of high-titer neutralizing antibodies, using hybrid human immunodeficiency virus V3-Ty viruslike particles in a clinically relevant adjuvant. J Virol 1991;65:450-456.
29. Kingsman AJ, Burns NR, Layton GT, and Adams SE: Yeast retrotransposon particles as antigen delivery systems. Ann NY Acad Sci 1995;754:202-213.
30. Crabbe MJC, Evans DJ, and Almond JW: Modelling of poliovirus. HIV-1 antigen chimaeras. FEBS Lett 1990;271:194-198.
31. Arnold GF, Resnick DA, Li Y, Zhang A, Smith AD, Geisler SC, Jacobo-Molina A, Lee W, Webster RG, and Arnold E: Design and construction of rhinovirus chimeras incorporating immunogens from polio, influenza, and human immunodeficiency viruses. Virology 1994;198:703-708.
32. Smith AD, Resnick DA, Zhang A, Geisler SC, Arnold E, and Arnold GF: Use of random systematic mutagenesis to generate viable human rhinovirus 14 chimeras displaying human immunodeficiency virus type 1 V3 loop sequences. J Virol 1994;68:575-579.
33. Luo L, Li Y, Cannon PM, Kim S, and Kang CY: Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodies. Proc Natl Acad Sci USA 1992;89: 10527-10531.
34. del Val M, Schlicht HJ, Volkmer HJ, Messerle M, Reddehase MJ, and Koszinowski UH: Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope. J Virol 1991;65:3641-3646.
35. Schodel F, Wirtz R, Peterson D, Hughes J, Warren R, Sadoff J, and Milich D: Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes. J Exp Med 1994;180:1037-1046.
36. Schödel F, Moriarty AM, Peterson DL, Zheng J, Hughes JL, Will H, Leturcq DJ, McGee JS, and Milich DR: The position of heterologous epitopes inserted in heptatitis B virus core particles determines their immunogenicity. J Virol 1992;66:106-114.
37. Borisova G, Arya B, Dislers A, Borschukova O, Tsibinogin V, Skrastina D, Eldarov M, Pumpens P, Skryabin KG, and Grens E: Hybrid hepatitis B virus nucleocapsid bearing immunodominant region from hepatitis B virus surface. J Virol 1993;67: 3696-3701.
38. Tindle RW, Herd K, Londono P, Fernando GJP, Chatfield SN, Malcolm K, and Dougan G: Chimeric hepatitis B core antigen particles containing B- and Th-epitopes of human papillomavirus type 16 E7 protein induce specific antibody and T-helper responses in immunised mice. Virology 1994;200:547-557.
39. Crowther RA, Kiselev NA, Böttcher B, Berriman JA, Borisova GP, Ose V, and Pumpens P: Three dimensional structure of hepatitis B virus core particles determined by electron cryo-microscopy. Cell 1994;77:943-950.
40. Berman PW, Gregory TJ, Riddle L, Nakamura GR, Champe MA, Porter JP, Wurm FM, Hershberg RD, Cobb EK, and Eichberg JW: Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature (London) 1990;345:622-625.
41. Berzofsky JA, Bensussan A, Cease KB, Bourge JF, Cheynier R, Lurhuma Z, Salaun JJ, Gallo R, Shearer GM, and Zagury D: Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans. Nature (London) 1988;334: 706-708.
42. Wahren B, Morfeldt-Mansson L, Biberfeld G, Moberg L, Sonnerborg A, Ljungman P, Werner A, Kurth R, Gallo R, and Bolognesi D: Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. J Virol 1987;61:2017-2023.
43. Clerici M, Stocks NI, Zajac RA, Boswell RN, Bernstein DC, Mann DL, Shearer GM, and Berzofsky JA: Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals. Nature (London) 1989;339:383-385.
44. Laurent AG, Krust B, Rey M-A, Montangnier L, and Hovanessian AG: Cell surface expression of several species of human immunodeficiency virus type 1 major core protein. J Virol 1989;63:4074-4078.
45. Weber JN, Clapham PR, Weiss RA, Parker D, Roberts C, Duncan J, Weller I, Carne C, Tedder RS, Pinching AJ, and Cheingsong-Popov R: Human immunodeficiency virus infection in two cohorts of homosexual men: Neutralising sera and association of anti-Gag antibody with prognosis. Lancet 1987;I:119-122.
46. Fyfe L, Maingay JP, Robinson AC, and Howie SE: Murine immune response to HIV-1 p24 core protein following subcutaneous, intraperitoneal and intravenous immunization. Immunology 1991;74:467-472.
47. Fyfe L, Maingay JP, and Howie SE: Murine HIV-1 p24 specific T lymphocyte activation by different antigen presenting cells: B lymphocytes from immunized mice present core protein to T cells. Immunol Lett 1993;35:45-50.
48. Pumpens P, Borisova GP, Crowther RA, and Grens E: HBV core particles as epitope carriers. Intervirology 1995;38:63-74.
49. Borisova G, Borschukova O, Skrastina D, Mezule G, Dislers A, Petrovskis I, Ose V, Gusars I, Pumpens P, and Grens E: Display vectors, I. Hepatitis B core particle as a display moiety. Proc. Latv. Acad. Sci. 1996; submitted.
50. Clerici M, Giorgi JV, Chou CC, Gudeman VK, Zack JA, Gupta P, Ho HN, Nishanian PG, Berzofsky JA, and Shearer GM: Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis 1992;165:1012-1019.
51. Rowland-Jones SL, Nixon DF, Aldhous MC, Gotch F, Ariyoshi K, Hallam N, Kroll JS, Froebel K, and McMichael A: HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet 1993;341:860-861.
52. De Maria A, Cirillo C, and Moretta L: Occurrence of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T cell activity in apparently uninfected children born to HIV-1-infected mothers. J Infect Dis 1994;170:1296-1299.